[Application Progress of Immune Checkpoint Inhibitors  in Oncogene-driven Advanced Non-small Cell Lung Cancer].

Tongmei Zhang, Baolan Li

Open access · greenAbstract readReview

In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.1field-weighted citation impact, top 52% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Matrine alkaloids modulating DNA damage repair in chemoresistant non-small cell lung cancer cells.BMC cancer · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Tongmei ZhangBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute,  Beijing 101149, China.

Baolan LiBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute,  Beijing 101149, China.

Beijing Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect. More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers. However, the timing of ICIs intervention, the therapeutic regimen and the predictive biomarkers are actually debated, underscoring the need to explore the potential interest of ICIs in these populations. .

Indexed as

OncogenesAnimalsAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsImmune Checkpoint InhibitorsLung neoplasmsOncogenePredictor

Identifiers

PMID33819969

DOI10.3779/j.issn.1009-3419.2021.101.04

PMCPMC8143967

OpenAlexW3145613672

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.